154 related articles for article (PubMed ID: 36645458)
61. Radiotherapy in combination with nivolumab for relapsed/refractory classical Hodgkin lymphoma: About two cases.
de Forceville L; Deau-Fischer B; Franchi P; Arsène-Henry A; Cassou Mounat T; Bouscary D; Kirova YM
Cancer Radiother; 2019 Jun; 23(3):232-239. PubMed ID: 31147173
[TBL] [Abstract][Full Text] [Related]
62. Novel Therapies in the Treatment of Hodgkin Lymphoma.
Andrade-Gonzalez X; Ansell SM
Curr Treat Options Oncol; 2021 Mar; 22(5):42. PubMed ID: 33755826
[TBL] [Abstract][Full Text] [Related]
63. Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma.
Qin Q; Nan X; Miller T; Fisher R; Teh B; Pandita S; Farach AM; Pingali SR; Pandita RK; Butler EB; Pandita TK; Iyer SP
Radiat Res; 2018 Sep; 190(3):322-329. PubMed ID: 29949442
[TBL] [Abstract][Full Text] [Related]
64. Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.
Carlo-Stella C; Ricci F; Dalto S; Mazza R; Malagola M; Patriarca F; Viviani S; Russo D; Giordano L; Castagna L; Corradini P; Santoro A
Oncologist; 2015 Mar; 20(3):323-8. PubMed ID: 25669663
[TBL] [Abstract][Full Text] [Related]
65. Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells.
Guolo F; Minetto P; Pesce S; Ballerini F; Clavio M; Cea M; Frello M; Garibotto M; Greppi M; Bozzo M; Miglino M; Passannante M; Marcolin R; Tedone E; Colombo N; Mangerini R; Bo A; Ruzzenenti MR; Carlier P; Serio A; Luchetti S; Dominietto A; Varaldo R; Candiani S; Agostini V; Ravetti JL; Del Zotto G; Marcenaro E; Lemoli RM
Front Immunol; 2021; 12():753890. PubMed ID: 34804039
[TBL] [Abstract][Full Text] [Related]
66. Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation.
Kaloyannidis P; Hertzberg M; Webb K; Zomas A; Schrover R; Hurst M; Jacob I; Nikoglou T; Connors JM
Br J Haematol; 2020 Feb; 188(4):540-549. PubMed ID: 31588564
[TBL] [Abstract][Full Text] [Related]
67. PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation.
Godfrey J; Bishop MR; Syed S; Hyjek E; Kline J
J Immunother Cancer; 2017; 5():11. PubMed ID: 28239465
[TBL] [Abstract][Full Text] [Related]
68. A review of pathobiology and therapies for classic Hodgkin lymphoma.
Khan M; Hagemeister F; Wang M; Ahmed S
Blood Rev; 2022 Sep; 55():100949. PubMed ID: 35396126
[TBL] [Abstract][Full Text] [Related]
69. Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin's lymphoma: a phase II, non-randomized controlled trial.
Hochberg J; Basso J; Shi Q; Klejmont L; Flower A; Bortfeld K; Harrison L; van de Ven C; Moorthy C; Islam H; Gerard P; Voss S; Cairo MS
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35584865
[TBL] [Abstract][Full Text] [Related]
70. Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma.
Tarekegn K; Colon Ramos A; Singh B; Sequeira Gross HG; Gupta S
World J Oncol; 2021 Aug; 12(4):81-84. PubMed ID: 34349851
[TBL] [Abstract][Full Text] [Related]
71. Outcomes Related to FDG-PET-CT Response in Patients With Hodgkin Lymphoma Treated With Brentuximab-Vedotin at Relapse or Consolidation.
Kedmi M; Khaustov P; Ribakovsy E; Benjamini O; Avigdor A
Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e929-e937. PubMed ID: 34366266
[TBL] [Abstract][Full Text] [Related]
72. High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin's lymphoma: a single-center experience of 50 patients.
Shim BY; Lee MA; Byun JH; Roh SY; Song CW; Park JN; Lee JW; Min WS; Hong YS; Kim CC
Korean J Intern Med; 2004 Jun; 19(2):114-20. PubMed ID: 15366643
[TBL] [Abstract][Full Text] [Related]
73. Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States.
Lurain K; Zarif TE; Ramaswami R; Nassar AH; Adib E; Abdel-Wahab N; Chintapally N; Drolen CE; Feldman T; Haykal T; Nebhan CA; Kambhampati S; Li M; Mittra A; Lorentsen M; Kim C; Drakaki A; Morse M; Johnson DB; Mangla A; Dittus C; Ravi P; Baiocchi RA; Chiao EY; Rubinstein PG; Yellapragada SV; LaCasce AS; Sonpavde GP; Naqash AR; Herrera AF
Clin Lymphoma Myeloma Leuk; 2024 Apr; ():. PubMed ID: 38714474
[TBL] [Abstract][Full Text] [Related]
74. Phase I study of brentuximab vedotin (SGN-35) in Japanese children with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma.
Koga Y; Sekimizu M; Iguchi A; Kada A; Saito AM; Asada R; Mori T; Horibe K
Int J Hematol; 2020 May; 111(5):711-718. PubMed ID: 31960285
[TBL] [Abstract][Full Text] [Related]
75. Immune checkpoint inhibitors in combination with radiotherapy as salvage treatment for relapsed/refractory classical Hodgkin lymphoma: A retrospective analysis in 12 patients.
Lucchini E; Rusconi C; Levis M; Ricci F; Santoro A; Ricardi U; Volpetti S; Matrone F; di Russo A; Caizzi M; Schiattarella A; Zaja F
Hematol Rep; 2021 Jun; 13(2):9080. PubMed ID: 34221295
[TBL] [Abstract][Full Text] [Related]
76. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.
Moskowitz AJ; Schöder H; Yahalom J; McCall SJ; Fox SY; Gerecitano J; Grewal R; Hamlin PA; Horwitz S; Kobos R; Kumar A; Matasar M; Noy A; Palomba ML; Perales MA; Portlock CS; Sauter C; Shukla N; Steinherz P; Straus D; Trippett T; Younes A; Zelenetz A; Moskowitz CH
Lancet Oncol; 2015 Mar; 16(3):284-92. PubMed ID: 25683846
[TBL] [Abstract][Full Text] [Related]
77. [Brentuximab vedotin treatment in patients with relapsed or refractory Hodgkin lymphoma. A Hungarian retrospective study].
Molnár Z; Pinczés LI; Piukovics K; Istenes I; Wolf K; Csukly Z; Szomor Á; Illés Á; Miltényi Z
Orv Hetil; 2017 Oct; 158(41):1630-1634. PubMed ID: 29025292
[TBL] [Abstract][Full Text] [Related]
78. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma.
Merryman RW; Castagna L; Giordano L; Ho VT; Corradini P; Guidetti A; Casadei B; Bond DA; Jaglowski S; Spinner MA; Arai S; Lowsky R; Shah GL; Perales MA; De Colella JMS; Blaise D; Herrera AF; Shouse G; Spilleboudt C; Ansell SM; Nieto Y; Badar T; Hamadani M; Feldman TA; Dahncke L; Singh AK; McGuirk JP; Nishihori T; Chavez J; Serritella AV; Kline J; Mohty M; Dulery R; Stamatoulas A; Houot R; Manson G; Moles-Moreau MP; Orvain C; Bouabdallah K; Modi D; Ramchandren R; Lekakis L; Beitinjaneh A; Frigault MJ; Chen YB; Lynch RC; Smith SD; Rao U; Byrne M; Romancik JT; Cohen JB; Nathan S; Phillips T; Joyce RM; Rahimian M; Bashey A; Ballard HJ; Svoboda J; Torri V; Sollini M; De Philippis C; Magagnoli M; Santoro A; Armand P; Zinzani PL; Carlo-Stella C
Leukemia; 2021 Sep; 35(9):2672-2683. PubMed ID: 33658659
[TBL] [Abstract][Full Text] [Related]
79. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
[TBL] [Abstract][Full Text] [Related]
80. Advances in Therapy for Relapsed or Refractory Hodgkin Lymphoma.
Choi Y; Diefenbach CS
Curr Oncol Rep; 2020 Jan; 22(1):6. PubMed ID: 31981025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]